International Biotechnology Trust plc
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies fo… Read more
International Biotechnology Trust plc (IBT) - Net Assets
Latest net assets as of August 2025: GBX249.41 Million GBX
Based on the latest financial reports, International Biotechnology Trust plc (IBT) has net assets worth GBX249.41 Million GBX as of August 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX284.04 Million) and total liabilities (GBX34.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX249.41 Million |
| % of Total Assets | 87.81% |
| Annual Growth Rate | -1.34% |
| 5-Year Change | -22.97% |
| 10-Year Change | 15.12% |
| Growth Volatility | 25.2 |
International Biotechnology Trust plc - Net Assets Trend (2000–2025)
This chart illustrates how International Biotechnology Trust plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for International Biotechnology Trust plc (2000–2025)
The table below shows the annual net assets of International Biotechnology Trust plc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | GBX249.41 Million | -11.64% |
| 2024-08-31 | GBX282.26 Million | +4.42% |
| 2023-08-31 | GBX270.32 Million | -5.11% |
| 2022-08-31 | GBX284.89 Million | -12.01% |
| 2021-08-31 | GBX323.77 Million | +14.05% |
| 2020-08-31 | GBX283.90 Million | +17.89% |
| 2019-08-31 | GBX240.82 Million | -8.25% |
| 2018-08-31 | GBX262.47 Million | +3.89% |
| 2017-08-31 | GBX252.65 Million | +16.62% |
| 2016-08-31 | GBX216.65 Million | -8.20% |
| 2015-08-31 | GBX236.00 Million | +9.78% |
| 2014-08-31 | GBX214.97 Million | +24.50% |
| 2013-08-31 | GBX172.67 Million | +33.94% |
| 2012-08-31 | GBX128.92 Million | +40.49% |
| 2011-08-31 | GBX91.76 Million | -2.02% |
| 2010-08-31 | GBX93.66 Million | -4.68% |
| 2009-08-31 | GBX98.25 Million | -13.44% |
| 2008-08-31 | GBX113.52 Million | +10.90% |
| 2007-08-31 | GBX102.36 Million | +52.89% |
| 2006-08-31 | GBX66.95 Million | +15.43% |
| 2005-08-31 | GBX58.00 Million | +5.17% |
| 2004-08-31 | GBX55.15 Million | +2.27% |
| 2003-08-31 | GBX53.93 Million | +12.60% |
| 2002-08-31 | GBX47.90 Million | -51.49% |
| 2001-08-31 | GBX98.74 Million | -71.73% |
| 2000-08-31 | GBX349.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to International Biotechnology Trust plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5808600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX10.35 Million | 4.15% |
| Other Comprehensive Income | GBX267.28 Million | 107.16% |
| Other Components | GBX29.87 Million | 11.98% |
| Total Equity | GBX249.41 Million | 100.00% |
International Biotechnology Trust plc Competitors by Market Cap
The table below lists competitors of International Biotechnology Trust plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVLL3F
SA:AVLL3F
|
$1.10K |
|
ADDvise Group AB BTA B
ST:ADDV-BTA-B
|
$1.10K |
|
Silver Scott Mines Inc
PINK:SILS
|
$1.10K |
|
Kubient Inc
NASDAQ:KBNT
|
$1.10K |
|
Wejo Group Limited
PINK:WEJOF
|
$1.10K |
|
Trophy Resources Inc
PINK:TRSI
|
$1.10K |
|
Vindicator Silver-Lead Mining Co
PINK:VINS
|
$1.10K |
|
NIGERIAN AVIATION HANDLING CO. PLC
XNSA:NAHCO
|
$1.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in International Biotechnology Trust plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 282,265,000 to 249,409,000, a change of -32,856,000 (-11.6%).
- Net loss of 1,170,000 reduced equity.
- Dividend payments of 11,196,000 reduced retained earnings.
- Share repurchases of 20,490,000 reduced equity.
- Other comprehensive income increased equity by 235,794,000.
- Other factors decreased equity by 235,794,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.17 Million | -0.47% |
| Dividends Paid | GBX11.20 Million | -4.49% |
| Share Repurchases | GBX20.49 Million | -8.22% |
| Other Comprehensive Income | GBX235.79 Million | +94.54% |
| Other Changes | GBX-235.79 Million | -94.54% |
| Total Change | GBX- | -11.64% |
Book Value vs Market Value Analysis
This analysis compares International Biotechnology Trust plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 129.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 787.18x to 129.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-08-31 | GBX1.15 | GBX908.00 | x |
| 2005-08-31 | GBX1.21 | GBX908.00 | x |
| 2006-08-31 | GBX1.41 | GBX908.00 | x |
| 2007-08-31 | GBX1.72 | GBX908.00 | x |
| 2009-08-31 | GBX1.48 | GBX908.00 | x |
| 2010-08-31 | GBX1.51 | GBX908.00 | x |
| 2011-08-31 | GBX1.56 | GBX908.00 | x |
| 2012-08-31 | GBX2.32 | GBX908.00 | x |
| 2013-08-31 | GBX3.12 | GBX908.00 | x |
| 2014-08-31 | GBX3.91 | GBX908.00 | x |
| 2015-08-31 | GBX5.37 | GBX908.00 | x |
| 2016-08-31 | GBX5.56 | GBX908.00 | x |
| 2017-08-31 | GBX6.73 | GBX908.00 | x |
| 2018-08-31 | GBX6.99 | GBX908.00 | x |
| 2019-08-31 | GBX6.33 | GBX908.00 | x |
| 2020-08-31 | GBX7.38 | GBX908.00 | x |
| 2021-08-31 | GBX8.00 | GBX908.00 | x |
| 2022-08-31 | GBX6.94 | GBX908.00 | x |
| 2023-08-31 | GBX6.66 | GBX908.00 | x |
| 2024-08-31 | GBX7.39 | GBX908.00 | x |
| 2025-08-31 | GBX7.02 | GBX908.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently International Biotechnology Trust plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.26%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.14x
- Recent ROE (-0.47%) is below the historical average (8.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 2.22% | 46.70% | 0.05x | 1.01x | GBX-4.29 Million |
| 2005 | -0.64% | -40.79% | 0.02x | 1.01x | GBX-6.17 Million |
| 2006 | 14.71% | 87.39% | 0.17x | 1.00x | GBX3.16 Million |
| 2007 | -2.11% | 0.00% | 0.00x | 1.02x | GBX-12.40 Million |
| 2009 | -8.48% | 0.00% | -0.07x | 1.00x | GBX-18.16 Million |
| 2010 | 1.14% | 33.40% | 0.03x | 1.02x | GBX-8.30 Million |
| 2011 | 4.98% | 62.83% | 0.07x | 1.10x | GBX-4.61 Million |
| 2012 | 29.48% | 97.83% | 0.30x | 1.00x | GBX25.12 Million |
| 2013 | 25.73% | 98.06% | 0.26x | 1.00x | GBX27.16 Million |
| 2014 | 20.80% | 97.82% | 0.20x | 1.05x | GBX23.22 Million |
| 2015 | 33.25% | 98.51% | 0.30x | 1.11x | GBX54.88 Million |
| 2016 | -3.33% | 0.00% | -0.03x | 1.07x | GBX-28.88 Million |
| 2017 | 17.91% | 97.63% | 0.17x | 1.08x | GBX19.99 Million |
| 2018 | 7.60% | 94.58% | 0.08x | 1.00x | GBX-6.29 Million |
| 2019 | -7.32% | 0.00% | -0.07x | 1.01x | GBX-41.50 Million |
| 2020 | 18.82% | 97.77% | 0.18x | 1.07x | GBX25.03 Million |
| 2021 | 8.61% | 95.75% | 0.08x | 1.07x | GBX-4.49 Million |
| 2022 | -7.89% | 0.00% | -0.06x | 1.15x | GBX-50.96 Million |
| 2023 | 2.52% | 80.21% | 0.03x | 1.13x | GBX-20.22 Million |
| 2024 | 13.77% | 91.82% | 0.14x | 1.09x | GBX10.65 Million |
| 2025 | -0.47% | -6.26% | 0.07x | 1.14x | GBX-26.11 Million |
Industry Comparison
This section compares International Biotechnology Trust plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,568,806
- Average return on equity (ROE) among peers: -151.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| International Biotechnology Trust plc (IBT) | GBX249.41 Million | 2.22% | 0.14x | $1.10K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |